Results 171 to 180 of about 1,177,456 (242)

Modern Concepts OF Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis is a pathological process in the lungs characterized by refractory to therapy and high mortality rates, it is a heterogeneous group of disorders with progressive and irreversible destruction of the lung architectonics due to
Zokirovna, O. A. (Olimova)
core  

Peripheral immune checkpoint gene expression as diagnostic biomarkers in idiopathic pulmonary fibrosis. [PDF]

Sarcoidosis Vasc Diffuse Lung Dis
Somuncu MN, Zamani A, Zamani AG, İnci A, Yıldırım MS.   +4 more
europepmc   +1 more source

Adipose‐Derived Mesenchymal Stem Cells: Isolation, Origin, Phenotype Applications, and Challenges

MedComm, Volume 7, Issue 11, November 2026.
Bridging basic biology to clinical translation, this review systematically explores the in vivo origins and evolving isolation techniques of AD‐MSCs. We dissect their diverse phenotype applications orchestrated by immunometabolic reprogramming, mitochondrial transfer, and extracellular vesicles.
Ziyang Liu, Guangming Tu, Chao Wang, Hongyan Zhao, Ziyi Wu, Wei Li, Li Chen, Bailin Niu   +7 more
wiley   +1 more source

Meaningful thresholds for change in quantitative computed tomography-derived fibrosis extent in idiopathic pulmonary fibrosis. [PDF]

Am J Respir Crit Care Med
Kim DY, Kim MJ, Oh YJ, Hwang HJ, Chae EJ, Lee SM, Park S, Lee JH, Seo JB, Lee HY, Kim HC, Choe J.   +11 more
europepmc   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang   +4 more
wiley   +1 more source

The impact of macrophage metabolism on idiopathic pulmonary fibrosis development and treatment prospectives. [PDF]

Front Immunol
Mu G, Chong S, Li J, Wang H, Meng H, Xiang Q, Cui Y.   +6 more
europepmc   +1 more source

Redefining CHI3L1: Therapeutic Opportunities at the Crossroads of Immune Suppression and Disease Progression

Medicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.
ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu, Saurabh Upadhyay, Moustafa T. Gabr   +2 more
wiley   +1 more source

Mitophagy in idiopathic pulmonary fibrosis: from molecular mechanisms to therapeutic opportunities. [PDF]

Front Cell Dev Biol
He M, Li Y, Huang H, Cong Z, Yang Y.
europepmc   +1 more source

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema

Respirology, Volume 31, Issue 11, Page 1117-1125, November 2026.
This multicentre prospective study of 1016 patients demonstrated that CPFE, defined as ≥ 5% emphysema on visual CT assessment, identified a high‐risk phenotype with significantly worse 5‐year survival compared to non‐CPFE IIP patients (51.4% vs. 63.1%) and COPD patients (51.4% vs. 84.0%) and higher acute exacerbation incidence, validating international
Kazuya Tsubouchi, Yasuaki Kotetsu, Tomotsugu Takano, Hiroaki Ogata, Fumiaki Kiyomi, Katsuyuki Ichiki, Shohei Takata, Yasuhiko Kitasato, Hiroshi Ishii, Kazuhiro Yatera, Kei Yamasaki, Masaki Okamoto, Makoto Yoshida, Masayuki Kawasaki, Masaki Fujita, Tomohiro Ogawa, Kazunori Tobino, Eiji Harada, Noriaki Nakagaki, Masashi Komori, Taishi Harada, Hiroshi Wataya, Yoichi Nakanishi, Isamu Okamoto   +23 more
wiley   +1 more source

Somatic mutation analysis of mucin genes and pathways in idiopathic pulmonary fibrosis. [PDF]

Am J Respir Crit Care Med
Seo MK, Blumhagen R, Cho MH, Schwartz DA, Yun JH.   +4 more
europepmc   +1 more source